Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $8.45
Previous CloseN/A
Volume547.29K
Average Volume (3M)1.60M
Market Cap
$456.63M
Enterprise Value$346.47M
Total Cash (Recent Filing)$117.57M
Total Debt (Recent Filing)$72.77M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 06, 2025EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding54,949,170
10 Day Avg. Volume2,114,318
30 Day Avg. Volume1,603,108
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)-12.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.40
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue17.09
Enterprise Value/Gross Profit57.74K
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$15.11Price Target Upside81.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Verastem News
Bulls Say, Bears Say
Bulls Say
Market PotentialThere is an estimated market opportunity of over $1.5 billion for KRAS mutant LGSOC due to the duration of therapy potentially exceeding one year.
Market ReachThe addition of Avmapki Fakzynja into the NCCN guidelines as a recommended treatment could significantly improve the combo’s usage in community healthcare centers and accelerate the company’s commercial efforts.
Regulatory ApprovalVerastem's avutometinib plus defactinib combination received accelerated approval from the FDA for the treatment of low-grade serous ovarian cancer, well ahead of its PDUFA date.
Bears Say
CompetitionVSTM is exploring additional opportunities in KRAS G12Cm NSCLC and 1L pancreatic cancer, with further clinical data expected to inform competitiveness and risk/reward.
Cost ConcernsVerastem's expected spending for the avutometinib + defactinib product launch will be efficient due to a collaboration with IQVIA.
Regulatory HurdlesThe RAMP-301 study will serve as a confirmatory trial for full approval and provide an opportunity to expand the label to KRAS WT patients.
Ownership Overview
1.22% Insiders
6.06% Mutual Funds
42.93% Other Institutional Investors
42.78% Public Companies and Individual Investors
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.10 and its highest was $8.45 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $456.63M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Aug 06, 2025 which is in 73 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on May 13, 2025. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.7 by -$0.26.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.63.
How many shares outstanding does Verastem have?
Verastem has 54,949,170 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.7. Following the earnings report the stock price went down -4.424%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.11 (81.83% Upside)
$15.11 (81.83% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 645.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $582.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.77%
12-Months-Change
Fundamentals
Return on Equity
-2159.50%
Trailing 12-Months
Asset Growth
6.60%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Stock 12 Month Forecast
Average Price Target
$15.11
▲( 81.83% Upside)
Technical Analysis
Rigel
―
Astria Therapeutics
―
Personalis
―
Aura Biosciences Inc
―
Amylyx Pharmaceuticals Inc
―